← All deals

DARE BIOSCIENCE, INC.

Public Equity (NASDAQ)BiotechnologyWomen's HealthPublic Company
📍 San Diego, CA, United States• Founded 2015
StreetZero Signal 40
Be the first to signal interest

About DARE BIOSCIENCE, INC.

Daré Bioscience, Inc. is a public biotechnology company focused on developing women's health treatments, including investigational products for HPV-related cervical disease, preterm birth prevention, and contraception. The company leverages non-dilutive grant funding from NIH and NIAID to advance its pipeline of intravaginal ring and other technologies. It trades on NASDAQ under DARE and has secured multiple grants totaling over $43 million for its programmable drug delivery platform.

LATEST FUNDINGRule 144
$382.26
Announced 2026-11-19
🔒

Unlock the full deal profile

Create a free account to see investors, key highlights, news, company details and the AI analysis for DARE BIOSCIENCE, INC..

Free plan includes 3 full deal profiles every month.

Investors

Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.

Key highlights

  • Received multiple NIH grants exceeding $43M in non-dilutive funding for women's health pipeline.
  • Initiating Phase 3 trial for Sildenafil and advancing DARE-HPV with NIAID support.
  • Granted Nasdaq extension to regain compliance via capital raising and equity improvement plan.
  • Reported $4.5M comprehensive loss in FY2024 while reducing G&A expenses by 24%.

Source document & SEC filing

The source SEC filing and the cached document are available to members only. Sign in to view and download them.

Sign in to view the filing Create free account